Akshay Vaishnaw
EVP OF RESEARCH & DEVELOPMENT
Biomedical Sciences
Alnylam PharmaceuticaIs Inc
United States of America
Biography
Dr. Akshay Vaishnaw joined Alnylam in 2006, coming from Biogen, Inc. (now Biogen Idec Inc.), where he was most recently Senior Director, Translational Medicine. In his 7 years at Biogen, Dr. Vaishnaw was involved in many aspects of clinical research and business development, and led the effort for the approval of AMEVIVE® (alefacept) for psoriasis. Dr. Vaishnaw received his MD from the University of Wales College of Medicine, UK, and his PhD from the University of London, UK, in Molecular Immunology. He is a Fellow of the Royal College of Physicians, UK. Dr. Vaishnaw is a member of the Scientific Advisory Board of Scholar Rock, and a member of the Board of Directors for Visterra, Inc., and for Editas Medicine. In addition, he has published papers in leading scientific journals and authored several textbook chapters relating to autoimmune disease.
Research Interest
Molecular Immunology,Translational Medicine,clinical research and business development
